Charles A Powell, MD, MBA
img_Charles A Powell
PROFESSOR | Medicine, Pulmonary, Critical Care and Sleep Medicine
Are you a patient?
Pulmonary Medicine (Lung), Internal Medicine, Critical Care
Multi-Disciplinary Training Area
Artificial Intelligence and Emerging Technologies in Medicine [AIET]
Lung adenocarcinoma can progress from an indolent in situ carcinoma to an invasive, aggressive, metastatic tumor. The WHO/IASLC/ATS Lung adenocarcinoma classification emphasizes the distinction of adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma from their invasive counterparts.  Molecular biomarkers of invasion can distinguish invasive from non-invasive tumors, a distinction that is typically difficult to make in small biopsies and cytology specimens and is becoming increasingly important as the recognition of early stage adenocarcinoma increases with the widespread implementation of lung cancer screening programs in the United States. Please visit the Charles Powell Lab.

MD, University of Chicago Pritzker School of Medicine

Residency, Internal Medicine, Columbia Presbyterian Medical Center

Fellowship, Pulmonary and Critical Care Medicine, Boston University Medical Center


American Board of Internal Medicine
Charles Powell, MD

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Powell during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Bristol-Myers Squibb
  • Duality Biologics
  • Astrazeneca
  • BioNTech
  • Clario
  • Daiichi Sankyo
  • Eisai, Inc.
  • Pfizer Pharmaceuticals
  • Senhwa Biosciences, Inc.
  • Aptar
  • Seagen
  • Silverback Therapeutics, Inc

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.